RE:Biogen Phase 1Thanks TB. Given the slightly more competitive landscape these days, I'd be good with a meager $10B, lol. Hopefully PMN's idea to collect biomarker data during Phase I could support the best-in-class hypothesis and chum the waters. Just demonstrating fewer ARIA E side effects at much higher doses would also be a big selling point. Exciting times ahead.